Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (gynecological Tumors)
This study is a single-arm, open clinical trial.This trial consists of two phases, dose-escalation and expansion, and the study process is divided into: a screening period, a sampling and production period, a NMA-LD chemotherapy period, a treatment and observation period, and a follow-up period.
Solid Tumor|Gynecological Tumors
BIOLOGICAL: GT316
Incidience and severity of adverse events per CTCAE 5.0, To characterize the safety profile of autologous TIL injection (GT316) in patients with relapsed/metastatic advanced solid tumor as measured by incidience and severity of adverse events per CTCAE 5.0, 3 years
This study is a single-arm, open clinical trial.This trial consists of two phases, dose-escalation and expansion, and the study process is divided into: a screening period, a sampling and production period, a NMA-LD chemotherapy period, a treatment and observation period, and a follow-up period.